glp-1/gip/glucagon triple agonist name GLP-1 / GIP / Glucagon Receptor (CAS 2381089-83-2) Dual and Triple Gut Peptide
Description
Khalaf RA, et al
Semaglutide is less effective at reducing body weight in T2D patients compared to patients without (5% weight loss, SUSTAIN-6 and 15% weight loss, STEP, respectively)
doi: 10.1016/j.tibs.2009.02.004
epub 27 Jul 2020
While the study was observational (meaning that causality cant be confirmed), it does add to the growing body of evidence suggesting that its worth investigating these weight-loss drugs as potential cancer prevention tools, says lead author, Professor Elizabeth McDonald
